$173 Million is the total value of Tamarack Advisers, LP's 41 reported holdings in Q2 2022. The portfolio turnover from Q1 2022 to Q2 2022 was 71.7% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CI | Sell | CIGNA CORPequity | $16,602,000 | -7.6% | 63,000 | -16.0% | 9.60% | +13.0% |
| LNTH | LANTHEUS HOLDINGS INCequity | $16,508,000 | +19.4% | 250,000 | 0.0% | 9.55% | +46.0% | |
| CERS | Buy | CERUS CORPequity | $10,580,000 | +16.8% | 2,000,000 | +21.2% | 6.12% | +42.8% |
| PCRX | Sell | PACIRA BIOSCIENCES INCequity | $10,203,000 | -34.8% | 175,000 | -14.6% | 5.90% | -20.3% |
| THC | Buy | TENET HEALTHCARE CORPequity | $8,410,000 | +30.4% | 160,000 | +113.3% | 4.87% | +59.5% |
| MDRX | Buy | ALLSCRIPTS HEALTHCARE SOLUTIequity | $8,157,000 | +81.1% | 550,000 | +175.0% | 4.72% | +121.4% |
| PRGO | New | PERRIGO CO PLCequity | $8,114,000 | – | 200,000 | +100.0% | 4.69% | – |
| UTHR | New | UNITED THERAPEUTICS CORPequity | $7,069,000 | – | 30,000 | +100.0% | 4.09% | – |
| SIBN | Buy | SI-BONE INCequity | $7,062,000 | -34.2% | 535,000 | +12.6% | 4.09% | -19.6% |
| MRK | Sell | MERCK & CO. INC.equity | $6,838,000 | -46.2% | 75,000 | -51.6% | 3.96% | -34.3% |
| ANGO | ANGIODYNAMICS INCequity | $6,192,000 | -10.2% | 320,000 | 0.0% | 3.58% | +9.8% | |
| PHR | Buy | PHREESIA INCequity | $6,127,000 | +32.8% | 245,000 | +40.0% | 3.54% | +62.4% |
| LH | New | LABORATORY CRP OF AMER HLDGSequity | $5,859,000 | – | 25,000 | +100.0% | 3.39% | – |
| AMGN | New | AMGEN INCequity | $5,839,000 | – | 24,000 | +100.0% | 3.38% | – |
| TPB | Sell | TURNING POINT BRANDS INCequity | $5,155,000 | -24.2% | 190,000 | -5.0% | 2.98% | -7.3% |
| BVS | Sell | BIOVENTUS INC - Aequity | $5,115,000 | -56.0% | 750,001 | -9.1% | 2.96% | -46.2% |
| SNY | New | SANOFI-ADRdepository receipt | $4,753,000 | – | 95,000 | +100.0% | 2.75% | – |
| ATRC | Buy | ATRICURE INCequity | $4,086,000 | -4.3% | 100,000 | +53.8% | 2.36% | +17.0% |
| JAZZ | New | JAZZ PHARMACEUTICALS PLCequity | $3,900,000 | – | 25,000 | +100.0% | 2.26% | – |
| VTRS | Buy | VIATRIS INCequity | $3,665,000 | +49.7% | 350,000 | +55.6% | 2.12% | +83.1% |
| BMRN | New | BIOMARIN PHARMACEUTICAL INCequity | $2,486,000 | – | 30,000 | +100.0% | 1.44% | – |
| RIGL | Sell | RIGEL PHARMACEUTICALS INCequity | $2,260,000 | -76.7% | 2,000,000 | -38.5% | 1.31% | -71.6% |
| ICUI | New | ICU MEDICAL INCequity | $2,137,000 | – | 13,000 | +100.0% | 1.24% | – |
| ISEE | Sell | IVERIC BIO INCequity | $1,924,000 | -69.1% | 200,000 | -45.9% | 1.11% | -62.2% |
| COLL | New | COLLEGIUM PHARMACEUTICAL INCequity | $1,772,000 | – | 100,000 | +100.0% | 1.02% | – |
| Buy | SOMALOGIC INCequity | $1,582,000 | -29.7% | 350,000 | +18.6% | 0.92% | -14.0% | |
| ASND | New | ASCENDIS PHARMA A/S - ADRdepository receipt | $1,394,000 | – | 15,000 | +100.0% | 0.81% | – |
| TCMD | Buy | TACTILE SYSTEMS TECHNOLOGY Iequity | $1,278,000 | -48.4% | 175,000 | +42.6% | 0.74% | -36.9% |
| Buy | DOCGO INCequity | $1,250,000 | +22.8% | 175,000 | +59.1% | 0.72% | +50.0% | |
| INMD | Sell | INMODE LTDequity | $1,121,000 | -76.6% | 50,000 | -61.5% | 0.65% | -71.4% |
| VRAY | Sell | VIEWRAY INCequity | $1,060,000 | -54.9% | 400,000 | -33.3% | 0.61% | -44.9% |
| NXGN | Buy | NEXTGEN HEALTHCARE INCequity | $1,046,000 | 0.0% | 60,000 | +20.0% | 0.60% | +22.2% |
| RDNT | RADNET INCequity | $864,000 | -22.8% | 50,000 | 0.0% | 0.50% | -5.5% | |
| Buy | DERMTECH INCequity | $554,000 | -24.5% | 100,000 | +100.0% | 0.32% | -7.5% | |
| CDNA | New | CAREDX INCequity | $537,000 | – | 25,000 | +100.0% | 0.31% | – |
| PLXS | Buy | PLEXUS CORPequity | $471,000 | +15.2% | 6,000 | +20.0% | 0.27% | +40.2% |
| New | TLT US 09/16/22 C125call | $318,000 | – | 2,500 | +100.0% | 0.18% | – | |
| New | GLD US 09/16/22 C180call | $288,000 | – | 1,500 | +100.0% | 0.17% | – | |
| TERRASCEND CORPequity | $171,000 | -60.0% | 75,000 | 0.0% | 0.10% | -51.2% | ||
| TCNNF | Sell | TRULIEVE CANNABIS CORPequity | $86,000 | -91.8% | 7,500 | -85.0% | 0.05% | -90.0% |
| New | SOMALOGIC INCwarrant | $15,000 | – | 20,000 | +100.0% | 0.01% | – | |
| VTRS | Exit | VTRS US 04/14/22 C15call | $0 | – | -3,000 | -100.0% | -0.02% | – |
| BAX | Exit | BAX US 05/20/22 P75put | $0 | – | -1,000 | -100.0% | -0.04% | – |
| CVS | Exit | CVS US 04/01/22 P101put | $0 | – | -1,000 | -100.0% | -0.05% | – |
| GLD | Exit | GLD US 06/17/22 C180call | $0 | – | -1,000 | -100.0% | -0.09% | – |
| AHCO | Exit | ADAPTHEALTH CORPequity | $0 | – | -20,000 | -100.0% | -0.15% | – |
| Exit | VERANO HOLDINGS CORPequity | $0 | – | -50,000 | -100.0% | -0.24% | – | |
| HOLX | Exit | HOLOGIC INCequity | $0 | – | -15,000 | -100.0% | -0.54% | – |
| PDCO | Exit | PATTERSON COS INCequity | $0 | – | -50,000 | -100.0% | -0.77% | – |
| SPY | Exit | SPY US 04/14/22 P440put | $0 | – | -4,000 | -100.0% | -0.86% | – |
| BCRX | Exit | BIOCRYST PHARMACEUTICALS INCequity | $0 | – | -125,000 | -100.0% | -0.96% | – |
| UNH | Exit | UNITEDHEALTH GROUP INCequity | $0 | – | -4,000 | -100.0% | -0.96% | – |
| CVET | Exit | COVETRUS INCequity | $0 | – | -129,000 | -100.0% | -1.02% | – |
| HSIC | Exit | HENRY SCHEIN INCequity | $0 | – | -50,000 | -100.0% | -2.06% | – |
| GILD | Exit | GILEAD SCIENCES INCequity | $0 | – | -75,000 | -100.0% | -2.11% | – |
| EXEL | Exit | EXELIXIS INCequity | $0 | – | -200,000 | -100.0% | -2.14% | – |
| Exit | JAZZ PHARMACEUTICALS PLCequity | $0 | – | -30,000 | -100.0% | -2.21% | – | |
| CVS | Exit | CVS HEALTH CORPequity | $0 | – | -50,000 | -100.0% | -2.40% | – |
| Exit | PERRIGO CO PLCequity | $0 | – | -175,000 | -100.0% | -3.18% | – | |
| MDT | Exit | MEDTRONIC PLCequity | $0 | – | -75,000 | -100.0% | -3.94% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-08-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| VERADIGM ORD | 32 | Q3 2023 | 13.9% |
| STREAMLINE HEALTH SOLUTIONS ORD | 30 | Q3 2023 | 4.0% |
| ATRICURE ORD | 29 | Q3 2023 | 7.6% |
| PACIRA PHARMACEUTICALS INC | 27 | Q1 2023 | 12.1% |
| LANTHEUS HOLDINGS ORD | 25 | Q4 2022 | 9.6% |
| MEDTRONIC PLC | 21 | Q1 2022 | 12.7% |
| RIGEL PHARMACEUTICALS ORD | 21 | Q2 2023 | 8.0% |
| BIO RAD LABORATORIES CL A ORD | 19 | Q2 2023 | 10.0% |
| HOLOGIC INC | 17 | Q1 2022 | 6.5% |
| SPY US 10/21/16 P210 | 17 | Q3 2023 | 41.5% |
View Tamarack Advisers, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| STREAMLINE HEALTH SOLUTIONS INC. | June 22, 2023 | 5,514,515 | 9.4% |
| IVERIC bio, Inc. | February 16, 2021 | 850,000 | 0.1% |
| Correvio Pharma Corp. | February 14, 2020 | 2,500,000 | 4.9% |
| OBALON THERAPEUTICS INC | February 14, 2020 | ? | ? |
| Correvio Pharma Corp. | February 15, 2019 | ? | ? |
| Corium International, Inc. | February 15, 2017 | 737,242 | 3.3% |
| ENDOLOGIX INC /DE/Sold out | February 15, 2017 | 0 | 0.0% |
| Imprivata IncSold out | February 15, 2017 | 0 | 0.0% |
View Tamarack Advisers, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-09 |
| 13F-HR | 2023-11-16 |
| 13F-HR | 2023-08-10 |
| SC 13D/A | 2023-06-22 |
| 13F-HR | 2023-05-11 |
| 13F-HR | 2023-02-13 |
| SC 13D/A | 2022-12-01 |
| 13F-HR | 2022-11-15 |
| 13F-HR | 2022-08-16 |
| 13F-HR | 2022-05-11 |
View Tamarack Advisers, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.